XenoPort, Inc.  

(Public, NASDAQ:XNPT)   Watch this stock  
Find more results for XNPT
After Hours: 7.04 -0.03 (-0.42%)
Jul 5, 4:12PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.35 - 7.86
Open     -
Vol / Avg. 0.00/3.04M
Mkt cap 447.86M
P/E     -
Div/yield     -
EPS -1.21
Shares 63.53M
Beta 1.94
Inst. own 80%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -103.12% -199.98%
Operating margin -97.29% -192.47%
EBITD margin - -190.75%
Return on average assets -37.19% -57.35%
Return on average equity -414.36% -147.73%
Employees 214 -
CDP Score - -


2000 Seaport Blvd Ste 300
REDWOOD CITY, CA 94063-5584
United States - Map
+1-408-6167200 (Phone)
+1-408-6167210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease.